VR Logo

TScan Therapeutics Inc. (TCRX) download report


Healthcare | Biotechnology & Pharma Research

TScan Therapeutics Inc. (TCRX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

IPO Date: 16-Jul-2021

Pres, CEO & Director: Mr. David P. Southwell

Sr. VP, CFO & Treasurer: Mr. Brian Michael Silver J.D.

Listing: NASDAQ: TCRX

Country: United States

Headquarters: Waltham, MA

Website: https://www.tscan.com

Key Facts

Market cap: $74.50 Mln

Revenue (TTM): $11.14 Mln

Earnings (TTM): $-56.87 Mln

Cash: $140.84 Mln

Total Debt: $5.65 Mln

Insider's Holding: 12.72%

Liquidity: Low

52 Week range: $1.60 - 14.71

Shares outstanding: 1,88,88,100

Stock Performance

Time Period TScan Therapeutics (TCRX) S&P BSE Sensex S&P Small-Cap 600
YTD-28.89-9.18-18.78
1 month1.27-4.78-8.00
3 months14.29-9.66-13.65
1 Year--0.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022